Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
A whale stranded at a Baltic Sea resort has swum off a sandbank. But it isn't safe yet - 2Germany expresses 'great concern' over Israel's new death penalty law
- 3From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- 4Want to read more in 2026? Here's how to revive your love of books
- 5Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- Exploring Being a parent: A Survey of \Bits of knowledge and Guidance for Guardians\ Nurturing Book
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- The most effective method to Alter Your Savvy Bed for A definitive Rest Insight
- Single women risk rape and exploitation in search for better life in Europe
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- Weeks-Long Australian LNG Outage Will Further Tighten Supply
- Sally Rooney books may be withdrawn from UK sale over Palestine Action ban, court told
- They grew up with 'almond moms.' Now, they dread going home for the holidays.
